Biopharmaceuticals - Epigenetics / Clinical Stage Development
Strategic Profile
The company develops proprietary drug candidates through clinical Phase II, at which point it decides on a case-by-case basis to either keep development in-house or partner or out-license the compound for late stage development and commercialization. The company has a strong intellectual property position and originates and owns all its IP portfolio, created internally through a concerted effort of its functional genomics, medicinal chemistry, preclinical and clinical development teams.
Cyborg Score Rationale
Oryzon maintains a strong IP position as a European leader in epigenetics therapeutics with multiple Phase II assets. However, as a clinical-stage company with no approved products, it faces execution risk, cash burn concerns, and pipeline dependency. Recent analyst sentiment shows mixed performance relative to market benchmarks.
Top Insights
Leading European player in epigenetics-based drug development with internally-created IP portfolio across CNS, oncology, and hematology
Phase II pipeline includes iadademstat (LSD1 inhibitor) for oncology and vafidemstat (CNS-optimized LSD1 inhibitor) for neurological disorders
Strategic development model balances in-house development through Phase II with partnership flexibility for late-stage commercialization
Well-supported by experienced international management and has attracted specialized investors from US, Israel, and Europe
Named Competitors
HDAC inhibitors/LSD1 inhibitors — Competing epigenetics-based therapeutic approaches in oncology and CNS
Recent Developments
(December 2025) Celebrated 10th anniversary since listing on Spanish Stock Exchange
(March 2026) Analyst price target of 7.067 EUR with 3 buy recommendations and +122% upside potential noted
Open the full interactive Oryzon Genomics S.A. report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.